OPK Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

139.76M

-23.88%

-0.068

-777%

130.80M

-12.74%

-0.060

-40%

137.18M

-12.52%

-0.058

-69.47%

Estimates Revision

The market is revising Downward the revenue expectations for OPKO Health, Inc. (OPK) for FY2025, with the revenue forecasts being adjusted by -6.86% over the past three months. During the same period, the stock price has changed by -0.35%.

Revenue Estimates for FY2025

Revise Downward

-6.86%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-8.55%

In Past 3 Month

Stock Price

Go Down

-0.35%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast OPK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPK is 2.75 USD with a low forecast of 2.25 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.375

Low

2.25

Averages

2.75

High

3.00

Current: 1.375

Low

2.25

Averages

2.75

High

3.00

JPMorgan

Neutral

initiated

2025-11-20

Reason

JPMorgan

Price Target

2025-11-20

initiated

Neutral

Reason

JPMorgan initiated coverage of Opko Health with a Neutral rating and no price target. The firm says Opko is a "multi-faceted" healthcare company, focusing in clinical diagnostics services through BioReference Labs operations and therapeutics development through its ModeX subsidiary. The company's clinical-stage pipeline portfolio remains early stage and needs clinical validation before "buy-in from investors," the analyst tells investors in a research note. JPMorgan awaits clinical validation before recommending the shares.

Jefferies

Buy

Hold

downgrade

2025-10-30

Reason

Jefferies

Price Target

2025-10-30

downgrade

Buy

Hold

Reason

Jefferies downgraded Opko Health to Hold from Buy with a price target of $1.60, down from $2. The firm, which is lowering Ngenla out-year estimates, says Opko's drug pipeline has potential, but is still early with a need for clarity on catalysts.

JPMorgan

Neutral

initiated

2025-04-25

Reason

JPMorgan

Price Target

2025-04-25

initiated

Neutral

Reason

JPMorgan initiated coverage of Opko Health with a Neutral rating and no price target. Following a series of asset sales and monetizing transactions, Opko is closing in on its goal of becoming a self-funded biotech company, the analyst tells investors in a research note. However, the firm believes it will take a series of clinical wins to gain broader investor recognition, with shares likely to trade range-bound over the mid-term.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-04-07

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-04-07

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-03-19

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-03-19

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-03-12

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-03-12

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for OPKO Health Inc (OPK.O) is -5.69, compared to its 5-year average forward P/E of 83.51. For a more detailed relative valuation and DCF analysis to assess OPKO Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

83.51

Current PE

-5.69

Overvalued PE

443.40

Undervalued PE

-276.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-20.81

Current EV/EBITDA

-13.34

Overvalued EV/EBITDA

15.53

Undervalued EV/EBITDA

-57.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.72

Current PS

1.95

Overvalued PS

2.11

Undervalued PS

1.33

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 1295.35% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1498.79% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 1295.35% over the last month.

Sold

Bought

OPK News & Events

Events Timeline

No data

News

3.0

12-09NASDAQ.COM

Reasons to Keep OPKO Health Stock in Your Portfolio at This Time

5.0

11-21NASDAQ.COM

Insider Buying Update for Friday, November 21: GLOO, OPK

9.5

11-13PRnewswire

NextPlat Reports Third Quarter 2025 Results

People Also Watch

Frequently Asked Questions

What is OPKO Health Inc (OPK) stock price today?

The current price of OPK is 1.3752 USD — it has decreased -0.36 % in the last trading day.

What is OPKO Health Inc (OPK)'s business?

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

What is the price predicton of OPK Stock?

What is OPKO Health Inc (OPK)'s revenue for the last quarter?

OPKO Health Inc revenue for the last quarter amounts to 151.67M USD, decreased -12.65 % YoY.

What is OPKO Health Inc (OPK)'s earnings per share (EPS) for the last quarter?

OPKO Health Inc. EPS for the last quarter amounts to 0.03 USD, decreased -25.00 % YoY.

What changes have occurred in the market's expectations for OPKO Health Inc (OPK)'s fundamentals?

How many employees does OPKO Health Inc (OPK). have?

OPKO Health Inc (OPK) has 2997 emplpoyees as of December 15 2025.

What is OPKO Health Inc (OPK) market cap?

Today OPK has the market capitalization of 1.06B USD.